ReportsWeb- Rheumatoid Arthritis - Global Drug Forecast and Ma

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025 published “Rheumatoid Arthritis Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over six million individuals in the 8MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, and Australia) and this prevalence is expected to grow to just shy of 7 million individuals by 2025. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2015 and 2025. With the anti-TNFs as extremely effective for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars launch across the 8MM and begin to gain traction in these markets. For more information about this report: arthritis-global-drug-forecast-and-market-analysis-to-2025 Scope - Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations. - Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets. - Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte's Olumiant (baricitinib), novel biologics (such as AstraZeneca- MedImmune's mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizer's Inflectra/Remsima, Samsung Bioepis/Biogen/Merck's Flixabi and Benepali, Sandoz's Erelzi, and Amgen's Amjevita). - Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Request Sample Copy at